Highly motivated postdoctoral candidates are invited to lead three different new projects in the laboratory of Jeffrey Rothstein MD, PhD:
Nuclear Biology in Neurodegeneration: to address fundamental questions on implicating nuclear pore complex and nuclear transport in dementia and ALS (Donnelley et al, Neuron, 2013; Zhang et al Nature 2015; Grima et al, Neuron 2017; Eftekharzadeh, Neuron 2018; Zhang et al, Cell, 2018,)) and other related neurodegenerative diseases
Astroglial subtypes and their role in synaptic maintenance in neurodegeneration and development. Focussing on newly discovered layer-specific cortical astroglial that regulate the growth of dendritic spines via Norrin (Miller at al, Nature, 2019).
Oligodendroglia/Oligodendroglial precursors: their role in neurodegeneration/ axonal maintenance and nuclear pore complex development and dysfunction (Lee et al, Nature, 2012; Kang et al, Nat Neurosci, 2013).
Experimental approaches, including biochemistry, genetics, molecular imaging and cell biology, from human and in vivo/in vitro rodent to mammalian systems are employed. New techniques applied in the lab include iPSC, genome editing, single cell analysis, and metabolic studies. Access to the largest library of human iPS cell lines (<650) for ALS and dementia along with full omics data as well. Candidates with a strong background in molecular, cellular biology, and/or biochemistry are encouraged to apply.
The Johns Hopkins Medical Institutions provide a stimulating and collaborative environment for biomedical research. Our lab is located in the Brain Science Institute and affiliated with the Depts of Neurology and Neuroscience at the School of Medicine. The Baltimore/Washington D.C. area also offers rich professional and living (county hiking and water activities) opportunities.
Candidates should have a doctoral degree and a strong research background. Candidates should have a PhD preferably in neuroscience or neuroscience-related disciplines: physiology, pharmacology, biology, anatomy, etc. Fluent in English; Background in general molecular biology, PCR, protein biology, histology, Confocal imaging.
Please send a statement of research experience and career goals, a copy of Curriculum Vitae, and contact information of at least one reference to Dr. Jeffrey D. Rothstein at firstname.lastname@example.org. Candidates must be US citizen, green card holder or holder of US Visa.
3 openings. Employer will assist with relocation costs.
Internal Number: 1
About Johns Hopkins University- Brain Science Institute
Jeffrey D. Rothstein, M.D., Ph.D. is the John W. Griffin Director for the Brain Science Institute, as well as a Professor of Neurology and Neuroscience, and the Founding Director of the Robert Packard Center for ALS Research at Johns Hopkins University School of Medicine. He received his BA in Neuroscience from Colgate University (1977), along with an MA in Neurochemistry-Biopsychology from the University of Chicago (1979). He received his PhD in Physiology and Biophysics-Neurochemistry (1984), and MD (1985) at the University of Illinois College of Medicine and Health Sciences Center. He completed a medical University of North Carolina , Chapel Hill and his neurology residency (1989) and neuromuscular fellowship (1991) at Johns Hopkins University. In 1991, Dr. Rothstein accepted a position as Assistant Professor in the Department of Neurology. In 2000, in addition to being promoted to his current position as Professor of Neurology and Neuroscience, Dr. Rothstein became the Director and Founder of the Robert Packard Center for ALS Research, which has raised approximately $130 million to date. In 2011, he became the Director of the Johns Hopkins Brain Science Institute; a University ...Wide Translational Neuroscience institute founded on a $100mil gift. A respected and internationally renowned neuroscientist, Dr. Rothstein is credited as being one of the world’s top clinical and basic ALS researcher and has over 30 years as a clinician scientist studying ALS pathophysiology, astrocyte/oliogodendroglial biology and therapy discovery; it was his research on ALS pathogenesis that lead to the first successful, FDA-approved drug to alter neurodegeneration in ALS. More recently his group has defined the basic cellular defect in nuclear transport/pores that underlie a large percentage of ALS, Huntington’s disease and Alzheimer’s dementia patients. He holds patents for candidate therapeutics and started a biotech company to help develop drugs and PET ligands for neurodegeneration. In addition to running an ALS clinic at Johns Hopkins which evaluates and manages over 400 ALS patients every year, he also runs a Brain Science Institute drug discovery group to identify novel therapeutics for neurological and psychiatric disease. Dr. Rothstein has received numerous awards for his work in the field of ALS and basic-to-clinical science, such as the Sheila Essay Award recognizing his worldwide contribution to ALS research, and the Diamond Award for ALS research, as well as the Lois Pope Foundation award for medical research, the Swiss Hartmann Muller Prize and more.